Biotech Firm Altimmune Faces Pivotal Week with Key Financial and Clinical Updates

This week represents a critical juncture for Altimmune as the biopharmaceutical company prepares to release its third-quarter 2025 financial results on Thursday. Market analysts project challenging figures, anticipating revenue to plummet by nearly 89 percent to just $560,000. The company’s per-share loss is estimated at -$0.29.

Beyond the quarterly numbers, investor attention remains fixed on the development progress of pemvidutide, the company’s flagship therapeutic candidate. This investigational treatment is being evaluated for multiple liver and metabolic conditions. Recent data from a Phase 2b clinical trial in metabolic dysfunction-associated steatohepatitis (MASH) demonstrated both rapid treatment effects and substantial weight reduction among participants.

The company is now preparing for crucial regulatory Read more...